Logo image of BCTX

BRIACELL THERAPEUTICS CORP (BCTX) Stock Fundamental Analysis

NASDAQ:BCTX - Nasdaq - CA1079301091 - Common Stock

0.406  +0.01 (+3.05%)

Premarket: 0.4001 -0.01 (-1.45%)

Fundamental Rating

0

BCTX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. BCTX may be in some trouble as it scores bad on both profitability and health. BCTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BCTX had negative earnings in the past year.
BCTX had a negative operating cash flow in the past year.
In the past 5 years BCTX always reported negative net income.
BCTX had a negative operating cash flow in each of the past 5 years.
BCTX Yearly Net Income VS EBIT VS OCF VS FCFBCTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

BCTX has a Return On Assets of -81.59%. This is in the lower half of the industry: BCTX underperforms 69.73% of its industry peers.
Industry RankSector Rank
ROA -81.59%
ROE N/A
ROIC N/A
ROA(3y)-73.12%
ROA(5y)-202.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCTX Yearly ROA, ROE, ROICBCTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K 1.5K

1.3 Margins

BCTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCTX Yearly Profit, Operating, Gross MarginsBCTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

BCTX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BCTX has been increased compared to 5 years ago.
BCTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCTX Yearly Shares OutstandingBCTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
BCTX Yearly Total Debt VS Total AssetsBCTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -35.94, we must say that BCTX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -35.94, BCTX is doing worse than 92.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -35.94
ROIC/WACCN/A
WACCN/A
BCTX Yearly LT Debt VS Equity VS FCFBCTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

A Current Ratio of 0.49 indicates that BCTX may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.49, BCTX is doing worse than 93.81% of the companies in the same industry.
A Quick Ratio of 0.49 indicates that BCTX may have some problems paying its short term obligations.
BCTX has a Quick ratio of 0.49. This is amonst the worse of the industry: BCTX underperforms 93.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
BCTX Yearly Current Assets VS Current LiabilitesBCTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.00% over the past year.
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.58%
EPS Next 2Y28.97%
EPS Next 3Y20.5%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCTX Yearly Revenue VS EstimatesBCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
BCTX Yearly EPS VS EstimatesBCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BCTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCTX Price Earnings VS Forward Price EarningsBCTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCTX Per share dataBCTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

BCTX's earnings are expected to grow with 20.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.97%
EPS Next 3Y20.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BCTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

NASDAQ:BCTX (1/22/2025, 8:06:51 PM)

Premarket: 0.4001 -0.01 (-1.45%)

0.406

+0.01 (+3.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-12 2024-12-12/amc
Earnings (Next)N/A N/A
Inst Owners12.87%
Inst Owner Change0.08%
Ins Owners3.36%
Ins Owner Change0%
Market Cap17.95M
Analysts80
Price TargetN/A
Short Float %4.36%
Short Ratio1.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.24%
Min EPS beat(2)86.67%
Max EPS beat(2)119.8%
EPS beat(4)2
Avg EPS beat(4)-55.01%
Min EPS beat(4)-251.48%
Max EPS beat(4)119.8%
EPS beat(8)5
Avg EPS beat(8)-22.46%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)8%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.93
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS-0.05
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81.59%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.12%
ROA(5y)-202.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 544.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -35.94
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y20.58%
EPS Next 2Y28.97%
EPS Next 3Y20.5%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.61%
OCF growth 3YN/A
OCF growth 5YN/A